Prasco Laboratories, a privately-held pharmaceutical company located in Mason, Ohio, has entered into an agreement with Shire for the distribution in the US of the authorized generic version of Carbatrol (Carbamazepine) extended-release capsules in 100 mg, 200 mg and 300 mg strengths.

Carbatrol is a medicine used to treat certain types of seizures (partial, tonic-clonic, mixed) and certain types of nerve pain (trigeminal and lossopharyngeal neuralgia). Carbatrol is not a regular pain medicine and should not be used for aches or pains.

Carbamazepine extended-release capsules are AB-rated, therapeutically equivalent and substitutable for the brand Carbatrol. The product will be distributed in the US under the Prasco label. Financial terms of the agreement were not disclosed.

 “We are pleased to provide Carbamazepine extended-release capsules to pharmacists and consumers,” said Prasco chief executive officer Christopher H. Arington. “As a Prasco Authorized Generic, Carbamazepine extended-release capsules will provide patients with a therapeutically equivalent product to the brand.”